Fig 2.
Antibody response to GEN-003/MM-2 vaccine formulation. C57BL/6 mice (n = 15) were immunized s.c. three times at three-week intervals with the GEN-003/MM-2 vaccine formulation (2 μg of each antigen plus 20 μg MM-2). Five mice per group received a fourth immunization 44 days after the third immunization. Serum samples were taken from five mice by cardiac puncture seven and 55 days after the third immunization and four days after the fourth immunization. (A) Serum samples were serially diluted 5-fold, and antibody titers to ICP4383-766 and gD2ΔTMR protein were measured by endpoint ELISA. IgG1 and IgG2c endpoint titers are shown as the mean ± the standard error of the mean (SEM) per group. (B) Neutralizing antibody titers to virus were determined using a colorimetric assay as described in Materials and Methods. Titers are shown as the mean ± SEM titer that resulted in 50% neutralizing activity per GEN-003/MM-2 vaccine-immunized group. No ELISA or neutralizing antibody titers were detected in serum from naïve mice or MM-2 adjuvant-immunized mice. P values were calculated by Student's t test. Data are representative of two experiments. NS, not significant.